Pure Global
NCT04040491

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Mingzhi Zhang·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mingzhi Zhang
Funder
Zhengzhou University
Location
Zhengzhou, China
Timeline & enrollment
Phase
Phase 4
Start date
Sep 01, 2019
End date
Sep 01, 2021
Enrollment
100 participants
Primary outcome

Overall Response Rate,Progression-free Survival,Overall Survival

Summary

To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and
 gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell
 lymphoma.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04040491
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04040491 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mingzhi Zhang and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.